

COMPUTER-AIDED DRUG DISCOVERY METHODS:

A BRIEF INTRODUCTION

Manos C. Vlasίου

Bentham Books

Computer-Aided Drug Discovery Methods: A Brief Introduction

Authored by

Manos C. Vlasiou
School of Veterinary Medicine
University of Nicosia
Nicosia, Cyprus

Eqo r wgt/Ck gf 'F t wi 'F kœqxt { 'O gj qf u<'C'Dt lghkvt qf wevkp

Author: Manos C. Vlasiou

ISBN (Online): 978-981-5305-03-6

ISBN (Print): 978-981-5305-04-3

ISBN (Paperback): 978-981-5305-05-0

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
CHAPTER 1 DRUG DISCOVERY	1
INTRODUCTION	1
Introduction to Drug Discovery	2
<i>Target Identification</i>	2
<i>Lead Generation</i>	2
<i>Lead Optimization</i>	3
<i>Preclinical Development</i>	3
<i>Clinical Development</i>	3
<i>Regulatory Approval</i>	3
<i>Post-Marketing Surveillance</i>	4
<i>Challenges and Advancements</i>	4
Target and Lead Identification: Unveiling the Path to Therapeutic Success	4
<i>Target Identification</i>	4
<i>Genetic Approaches</i>	4
<i>Proteomic Approaches</i>	5
<i>Chemical Biology Approaches</i>	5
<i>Lead Identification</i>	5
<i>High-Throughput Screening (HTS)</i>	5
<i>Virtual Screening</i>	5
<i>Natural Product Screening</i>	6
<i>Challenges and Advancements</i>	6
Drug Solubility: Unlocking Formulation Challenges for Effective Therapeutics	6
<i>Importance of Drug Solubility</i>	6
<i>Bioavailability</i>	7
<i>Formulation Development</i>	7
<i>Drug Delivery Systems</i>	7
Drug Likeness: Guiding Principles in Drug Design and Discovery	9
<i>Importance of Drug Likeness</i>	9
<i>Factors Influencing Drug Likeness</i>	9
Drug Databases: Empowering Drug Discovery and Knowledge Integration	10
<i>Importance of Drug Databases</i>	10
<i>Key Components of Drug Databases</i>	11
<i>Impact of Drug Databases</i>	12
Drug ADME: Understanding the Journey of a Drug in the Body	12
<i>Absorption</i>	12
<i>Distribution</i>	13
<i>Metabolism</i>	13
<i>Excretion</i>	13
Implications for Drug Development	13
<i>Bioavailability and Efficacy</i>	14
<i>Safety and Toxicity</i>	14
<i>Drug-Drug Interactions</i>	14
CONCLUSION	14
REFERENCES	15
CHAPTER 2 MOLECULAR DYNAMICS IN COMPUTER-AIDED DRUG DISCOVERY: UNVEILING INSIGHTS INTO BIOMOLECULAR INTERACTIONS	17
INTRODUCTION	17

Principles of Molecular Dynamics Simulations	18
<i>Newton's equations of motion</i>	18
Methodologies and Techniques	20
<i>System Setup and Preparation</i>	20
<i>System Definition</i>	20
<i>Force Field Selection</i>	20
<i>Initial Conditions</i>	20
<i>Simulation Box and Boundary Conditions</i>	21
<i>Solvent or Environment Setup</i>	21
<i>Energy Minimization and Equilibration</i>	21
<i>Solvent Models and Boundary Conditions</i>	22
<i>Treatment of Long-range Electrostatics</i>	23
<i>Force Field Parameterization and Validation</i>	23
Applications of Molecular Dynamics in Drug Discovery	25
<i>Protein-ligand Binding and Stability</i>	25
<i>Protein-protein Interactions</i>	25
<i>System Setup</i>	25
<i>Force Field Selection</i>	26
<i>Simulation Protocol</i>	26
<i>Binding Mechanism and Recognition</i>	26
<i>Allosteric Effects and Conformational Changes</i>	26
<i>Role of Water and Solvent Effects</i>	26
<i>Protein Dynamics and Conformational Changes</i>	27
<i>Membrane Protein Simulations</i>	27
<i>Membrane Model Selection</i>	27
<i>Force Field Selection</i>	27
<i>System Setup</i>	28
<i>Simulation Protocol</i>	28
<i>Lipid Dynamics and Protein-Lipid Interactions</i>	28
<i>Protein Conformational Changes and Function</i>	28
<i>Membrane Protein Dynamics and Allosteric Communication</i>	29
<i>Solvent Effects and Drug Permeability</i>	29
<i>Solvent Representation</i>	29
<i>Drug-Solvent Interactions</i>	29
<i>Membrane Permeability Studies</i>	30
<i>Free Energy Calculations</i>	30
<i>Transporter and Channel Interactions</i>	30
<i>Solvent Effects on Drug Binding</i>	30
Enhanced Sampling Methods	31
<i>Importance of Enhanced Sampling Techniques</i>	31
<i>Replica Exchange Molecular Dynamics (REMD)</i>	31
<i>Meta-dynamics and Biasing Potentials</i>	31
<i>Markov State Models (MSMs)</i>	31
Allosteric Modulation and Binding Site Identification	31
<i>Allosteric Modulation of Protein Function</i>	31
<i>Allosteric Site Identification and Characterization</i>	31
<i>Drug Design Targeting Allosteric Sites</i>	32
Drug Optimization and Binding Free Energy Calculation	32
<i>Free Energy Calculations in Drug Discovery</i>	32
<i>Ligand Binding Affinity Estimation</i>	32
<i>Free Energy Perturbation (FEP) and Thermodynamic Integration (TI)</i>	33

<i>Challenges and Limitations of Binding Free Energy Calculations</i>	33
Drug Resistance and Target Flexibility	33
<i>Understanding Drug Resistance Mechanisms</i>	33
<i>Simulating Drug-resistant Mutants</i>	34
<i>Flexibility in Target Proteins and its Implications</i>	34
<i>Flexible Docking and Hybrid Approaches</i>	34
<i>Integration with Experimental Techniques</i>	34
Advancements and Future Directions	38
<i>Accelerating MD Simulations with GPU Computing</i>	38
<i>Hybrid Methods: QM/MM and MD Simulations</i>	40
Challenges and Outlook	42
<i>Computational Cost and Scalability</i>	42
<i>Accuracy and Limitations of Force Fields</i>	43
CONCLUSION	45
REFERENCES	45
CHAPTER 3 PHARMACOPHORE MODELLING AND VIRTUAL SCREENING	48
INTRODUCTION	48
Pharmacophore Modelling: Unveiling the Key to Drug Design	49
<i>Understanding Pharmacophore Modelling</i>	49
<i>Process and Techniques</i>	49
<i>Significance in Drug Design</i>	50
<i>Applications in the Pharmaceutical Industry</i>	50
<i>Recent Advancements</i>	51
Virtual Screening	51
<i>Principles of Virtual Screening</i>	51
<i>Virtual Screening Approaches</i>	52
<i>Applications of Virtual Screening in Drug Discovery</i>	53
<i>Challenges in Virtual Screening</i>	53
<i>Integration of Virtual Screening with Experimental Approaches</i>	53
<i>Advancements in Virtual Screening</i>	53
<i>Future Perspectives</i>	54
QSAR Methods in Computer-Aided Drug Discovery	54
<i>Principles of QSAR</i>	54
<i>Development of QSAR Models</i>	54
<i>Applications of QSAR in Drug Discovery</i>	54
<i>Challenges and Limitations</i>	55
<i>Future Perspectives</i>	55
3D QSAR: Enhancing Drug Discovery through Three-Dimensional Quantitative Structure-Activity Relationship Analysis	55
<i>Importance of 3D QSAR</i>	55
<i>Principles of 3D QSAR</i>	56
<i>Applications of 3D QSAR</i>	57
Force Fields in Computer-Aided Drug Discovery: Unleashing the Power of Molecular Simulations	58
<i>Understanding Force Fields</i>	58
<i>Force Field Components</i>	58
<i>Parameterization and Validation</i>	58
<i>Applications in Computer-Aided Drug Discovery</i>	58
<i>Challenges and Future Perspectives</i>	59
CONCLUSION	60

REFERENCES	61
CHAPTER 4 MOLECULAR DOCKING IN COMPUTER-AIDED DRUG DISCOVERY: A POWERFUL TOOL FOR TARGETED THERAPEUTICS	63
INTRODUCTION	63
Principles of Molecular Docking	64
<i>Protein-ligand Interaction</i>	64
<i>Docking Algorithms</i>	65
<i>Scoring Functions</i>	66
<i>Validation and Accuracy Assessment</i>	68
Methodologies and Techniques	70
<i>Structure-based Drug Design</i>	70
<i>Ligand-based Drug Design</i>	72
<i>Virtual Screening</i>	73
Applications of Molecular Docking	75
<i>Target Identification and Validation</i>	75
<i>Target Identification</i>	75
<i>Target Validation</i>	76
<i>Lead Optimization and Hit-to-Lead Development</i>	77
<i>Hit-to-Lead Development</i>	77
<i>Lead Optimization</i>	78
<i>De Novo Drug Design</i>	79
Advancements in Molecular Docking	81
<i>Enhanced Scoring Functions</i>	81
<i>Fragment-based Docking</i>	83
<i>Solvent Effects and Explicit Water Modeling</i>	84
Challenges and Limitations	86
Future Perspectives and Outlook	86
<i>Integration of Machine Learning and AI</i>	87
<i>Multi-Target Docking and Polypharmacology</i>	87
<i>Incorporation of Dynamics and Flexibility</i>	87
<i>Improved Scoring Functions and Binding Free Energy Calculations</i>	87
<i>Integration of Structural and Experimental Data</i>	87
<i>Application to New Therapeutic Areas and Target Classes</i>	88
<i>Combination with Experimental High-Throughput Screening</i>	88
CONCLUSION	88
REFERENCES	89
CHAPTER 5 THE USE OF DENSITY FUNCTIONAL THEORY IN COMPUTER-AIDED DRUG DISCOVERY	91
INTRODUCTION	91
Principles of Density Functional Theory	91
<i>Electron Density</i>	92
<i>Kohn-Sham Equations</i>	92
<i>Exchange-Correlation Functional</i>	92
<i>Approximations</i>	92
<i>Energy and Property Calculations</i>	92
<i>Applications</i>	93
Application of Density Functional Theory in Drug Discovery	93
<i>Molecular Structure and Conformation</i>	93
<i>Electronic Properties and Spectroscopy</i>	93
<i>Reaction Energetics and Mechanisms</i>	93

<i>Binding Affinity and Drug-Receptor Interactions</i>	94
<i>Solvation Effects</i>	94
<i>Quantum Mechanical/Molecular Mechanical (QM/MM) Simulations</i>	94
<i>Virtual Screening and Drug Design</i>	94
Force Field Parameterization and Validation Using Functional Density Theory	95
<i>Force Fields in Molecular Dynamics</i>	95
<i>Limitations of Force Fields</i>	95
<i>Parameterization Process</i>	95
<i>Non-Bonded Parameters</i>	95
<i>Bonded Parameters</i>	96
<i>Validation</i>	96
<i>Iterative Refinement</i>	96
<i>Transferability and Limitations</i>	96
Solvent Effects and Continuum Solvation Models	96
<i>Solvent Effects in DFT</i>	97
<i>Continuum Solvation Models</i>	97
<i>Dielectric Continuum Models</i>	97
<i>Polarizable Continuum Models</i>	97
<i>Solvent Accessible Surface Area (SASA)</i>	97
<i>Implicit vs. Explicit Solvent Models</i>	98
Applications	98
Challenges and Future Directions in DFT for Drug Discovery	98
<i>Accuracy of Exchange-Correlation Functionals</i>	98
<i>Treatment of Solvation Effects</i>	99
<i>Time-Scale Limitations</i>	99
<i>Treatment of Excited States</i>	99
<i>Incorporating Quantum Effects</i>	99
<i>Data Availability and Integration</i>	99
<i>High-Throughput Screening and Virtual Screening</i>	100
<i>Multiscale Modeling and Integration</i>	100
CONCLUSION	100
REFERENCES	101

CHAPTER 6 SOFTWARE IN COMPUTER-AIDED DRUG DISCOVERY: EMPOWERING SCIENTIFIC EXPLORATION AND INNOVATION	103
INTRODUCTION	103
Molecular Modeling and Visualization Software	104
<i>Schrödinger Suite</i>	104
<i>PyMOL</i>	104
<i>Discovery Studio</i>	104
Molecular Docking and Virtual Screening Software	104
<i>Autodock</i>	105
<i>Gold (Genetic Optimization for Ligand Docking)</i>	105
<i>Dock</i>	105
Molecular Dynamics Simulation Software	105
<i>Gromacs</i>	105
<i>Amber (Assisted Model Building with Energy Refinement)</i>	105
<i>Namd</i>	105
Cheminformatics and Drug Design Software	105
<i>RDKit</i>	106
<i>Openeye</i>	106

<i>Moe (Molecular Operating Environment)</i>	106
Data Analysis and Machine Learning Software	106
<i>KNIME</i>	106
<i>TensorFlow</i>	106
<i>ChemMine Tools</i>	106
Hardware in Computer-Aided Drug Discovery: Empowering Computational Exploration and Accelerating Drug Development	106
<i>High-Performance Computing (HPC) Systems</i>	106
<i>Multi-Core Processors</i>	107
<i>Distributed Memory</i>	107
<i>Cluster Computing</i>	107
<i>Graphics Processing Units (GPUs) and Field-Programmable Gate Arrays (FPGAs)</i>	107
<i>Cloud Computing Platforms</i>	108
<i>Big Data Storage and Management</i>	108
The Role of Artificial Intelligence in Computer-Aided Drug Discovery: Revolutionizing Therapeutic Development	109
<i>Data Analysis and Integration</i>	109
<i>Predictive Modeling and Virtual Screening</i>	109
<i>De Novo Drug Design</i>	109
<i>Drug Repurposing and Combination Therapy</i>	110
CONCLUSION	110
REFERENCES	111
CHAPTER 7 SUCCESS STORIES IN COMPUTER-AIDED DRUG DISCOVERY	112
INTRODUCTION	112
Development of Imatinib for Chronic Myeloid Leukemia	113
<i>Target Identification</i>	113
<i>Virtual Screening</i>	113
<i>Structure-Based Drug Design</i>	113
<i>Pharmacophore Analysis</i>	114
<i>Clinical Validation and Success</i>	114
Development of Pembrolizumab for Cancer Immunotherapy	114
<i>Target Identification</i>	114
<i>Virtual Screening and Ligand Design</i>	114
<i>Molecular Docking and Binding Affinity Optimization</i>	115
<i>Predictive Modeling and Clinical Validation</i>	115
<i>Clinical Success and Impact</i>	115
Development of Sovaldi for Hepatitis C	115
<i>Target Identification</i>	115
<i>Structure-Based Drug Design</i>	116
<i>Virtual Screening and Drug Optimization</i>	116
<i>Pharmacokinetic Modeling</i>	116
<i>Clinical Success and Impact</i>	116
Development of Osimertinib for Non-Small Cell Lung Cancer	117
<i>Target Identification</i>	117
<i>Structure-Based Drug Design</i>	117
<i>Virtual Screening and Hit Optimization</i>	117
<i>Pharmacokinetic and Pharmacodynamic Modeling</i>	117
<i>Clinical Success and Impact</i>	118

Example of a Veterinary Drug Developed with Computer-Aided Drug Discovery, Galliprant (laropiprant), Used to Treat Pain and Inflammation Associated with Osteoarthritis in Dogs	118
<i>Virtual Screening and Ligand Design</i>	118
<i>Molecular Docking and Binding Analysis</i>	118
<i>Pharmacokinetic Modeling</i>	118
<i>Safety and Toxicity Prediction</i>	119
The Role of Computer-Aided Drug Discovery Techniques in the COVID-19 Pandemic: Accelerating Therapeutic Development and Understanding Viral Mechanisms	119
<i>Virtual Screening and Repurposing of Existing Drugs</i>	119
<i>Structure-Based Drug Design</i>	120
<i>Molecular Dynamics Simulations</i>	121
<i>Artificial Intelligence and Machine Learning</i>	122
CONCLUSION	122
REFERENCES	123
CHAPTER 8 THE FUTURE OF COMPUTER-AIDED DRUG DISCOVERY METHODS: ADVANCEMENTS AND OPPORTUNITIES	126
INTRODUCTION	126
Integration of Artificial Intelligence (AI)	126
High-Performance Computing (HPC)	127
Integration of Multi-Omics Data	127
Repurposing and Drug Combination Strategies	128
Quantum Computing	128
Integration of Blockchain Technology	128
Nanotechnology and Drug Delivery Systems	129
CONCLUSION	129
REFERENCES	129
SUBJECT INDEX	131

PREFACE

In the ever-evolving landscape of pharmaceutical research and development, the convergence of computational science and medicinal chemistry has ushered in a new era of innovation: Computer-Aided Drug Discovery (CADD). This exciting and rapidly advancing field represents a paradigm shift in identifying, designing, and optimizing novel therapeutics.

The journey from molecular target identification to clinical drug candidates is intricate and challenging, marked by complicated molecular interactions, complex biological systems, and an unyielding quest for efficacy and safety. In this intricate relationship between science and technology, CADD emerges as a guiding light, illuminating previously obscured pathways and accelerating drug discovery.

In this comprehensive volume, we embark on an exploration of the multifaceted world of Computer-Aided Drug Discovery. The chapters herein span a spectrum of methodologies, each contributing to our understanding of molecular interactions, predictive modeling, and rational design. From virtual screening and molecular docking to molecular dynamics simulations and machine learning algorithms, the tools at our disposal are diverse and robust.

Through the pages of this book, we delve into the intricacies of ligand-receptor interactions, binding free energy calculations, and the role of quantum mechanics in drug discovery. We examine the nuances of structure-based and ligand-based approaches while uncovering the potential of artificial intelligence and deep learning in unraveling the mysteries of molecular recognition.

However, as we navigate this fascinating domain, it is crucial to remember that CADD is not a panacea but a complementary force that enhances the ingenuity of medicinal chemists and biologists. The synergy between computational methods and experimental validation is the cornerstone of successful drug discovery.

As we venture further into the frontiers of drug discovery, the collective efforts of researchers, practitioners, and pioneers in CADD are reshaping the landscape of pharmaceutical science. The promise of more efficient, cost-effective, and targeted therapies is becoming a reality driven by the fusion of human intellect and computational power.

This book serves as both a reference and an inspiration, guiding us toward a future where Computer-Aided Drug Discovery is an essential pillar of modern healthcare, enhancing our ability to alleviate suffering and improve the human condition.

Onward to the future of drug discovery.

Manos C. Vlasiou
School of Veterinary Medicine
University of Nicosia
Nicosia, Cyprus

CHAPTER 1**Drug Discovery**

Abstract: Drug discovery is a complex process involving target identification, lead generation, and clinical development. Recent breakthroughs in genomics and AI-driven approaches have expedited target identification. Rational drug design and advanced chemistry techniques have improved lead compound optimization—preclinical testing benefits from organ-on-a-chip systems and 3D cell culture models. Clinical development is enhanced by personalized medicine and innovative trial designs. Across all stages, big data, machine learning, and AI play pivotal roles in data analysis and candidate selection. Collaboration between academia, industry, and regulators fosters a more efficient drug development ecosystem. These advancements offer promising prospects for tackling challenging diseases and enhancing global healthcare.

Keywords: Computer-aided drug discovery, Drug discovery methods, Drug-likeness, Solubility, Target identification.

INTRODUCTION

Drug discovery is a complex and dynamic process involving identifying and developing novel therapeutic agents to combat human diseases. It encompasses a multidisciplinary approach, integrating biology, chemistry, pharmacology, and computational sciences [1]. Here, we explore the stages of drug discovery, including target identification, lead generation, lead optimization, and preclinical and clinical development, and highlight the challenges and advancements in this field. Target and lead identification are critical stages in drug discovery, laying the foundation for developing novel therapeutic agents. Target identification involves identifying and validating a specific molecule or pathway implicated in a disease.

In contrast, lead identification focuses on discovering compounds that interact with the target and show potential therapeutic activity [2]. We will now explore the methodologies, challenges, and advancements in target and lead identification, highlighting their importance in pursuing effective treatments.

Drug solubility is crucial in pharmaceutical development, directly influencing drug bioavailability, formulation, and therapeutic efficacy. Poor solubility remains

a significant challenge in drug discovery and formulation, limiting the successful delivery of many potential therapeutic agents. We will shed some light on the significance of drug solubility, the factors affecting solubility, and the strategies employed to enhance solubility and improve drug formulations.

Drug likeness is a concept that serves as a guiding principle in drug design and discovery, aiming to identify compounds with properties favourable for their development into safe and effective medications. It involves the evaluation of a molecule's physicochemical and structural characteristics against a set of desirable attributes to assess its potential as a drug candidate [3]. The significance of drug-likeness, the factors influencing it, and its role in optimizing the success of drug development will be discussed.

Drug databases are pivotal in pharmaceutical research and development, providing comprehensive and structured repositories of drug-related information [4]. They are invaluable resources for drug discovery, development, and clinical decision-making.

ADME is an acronym that represents the four essential processes a drug undergoes within the body: absorption, distribution, metabolism, and excretion [5]. These processes collectively determine a drug's pharmacokinetic profile, influencing its bioavailability, distribution to target tissues, metabolism, and elimination. We will also explore the significance of the drug ADME, the critical processes involved, and their implications for drug development and therapeutic outcomes [6].

Introduction to Drug Discovery

Target Identification

The first crucial step in drug discovery is identifying a target, a specific protein, enzyme, receptor, or genetic component involved in a disease pathway. Advances in genomics, proteomics, and bioinformatics have revolutionized target identification, enabling researchers to uncover new therapeutic targets and understand disease mechanisms at a molecular level [7]. Target validation, utilizing various experimental and computational techniques, is essential to establish the significance and feasibility of the target for drug intervention.

Lead Generation

Once a target is identified, the next step is to find lead compounds that interact with the target and exhibit potential therapeutic activity. Lead generation involves screening large libraries of compounds, either through **high-throughput**

screening (HTS) or virtual screening methods. HTS involves testing thousands or even millions of combinations for their ability to bind to the target and elicit the desired biological response [8]. Virtual screening, on the other hand, employs computational techniques to screen and prioritize compounds based on their predicted interactions with the target.

Lead Optimization

After obtaining promising lead compounds, the focus shifts to lead optimization, which aims to enhance the compounds' potency, selectivity, and pharmacokinetic properties. Medicinal chemists modify the chemical structure of lead compounds through iterative rounds of synthesis, testing, and structure-activity relationship (SAR) studies [9]. The goal is to optimize the balance between efficacy, safety, and drug-like properties, guided by insights gained from molecular modelling, QSAR methods, and computational chemistry tools.

Preclinical Development

In the preclinical development stage, lead compounds undergo rigorous testing to assess their safety, efficacy, and pharmacokinetic profiles before progressing to clinical trials. Preclinical studies involve *in vitro* experiments, animal models, and toxicology assessments to evaluate the compound's pharmacological effects, potential side effects, and overall toxicity profile [10]. These studies provide crucial data for determining the candidate compound's dosage range, formulation, and possible therapeutic indications.

Clinical Development

If a lead compound successfully passes the preclinical evaluation, it progresses to clinical development, which involves testing the combination in humans through clinical trials. Clinical trials are conducted in phases, starting with Phase I, which focuses on safety and dosage determination, followed by Phase II and Phase III trials that assess efficacy, side effects, and comparative effectiveness against existing treatments [11]. These trials involve large patient populations and are tightly regulated to ensure patient safety and ethical conduct.

Regulatory Approval

The drug development process enters the regulatory phase upon completion of clinical trials. Pharmaceutical companies compile extensive data from preclinical and clinical studies and information on manufacturing processes, quality control, and safety measures to submit a **New Drug Application** (NDA) or equivalent to regulatory authorities such as the **Food and Drug Administration** (FDA) [12].

CHAPTER 2

Molecular Dynamics in Computer-Aided Drug Discovery: Unveiling Insights into Biomolecular Interactions

Abstract: Computer-aided drug discovery (CADD) has revolutionized the field of pharmaceutical research by providing efficient tools for predicting and optimizing drug-target interactions. Molecular dynamics (MD) simulations, an essential technique within CADD, play a crucial role in understanding the dynamic behavior of biomolecules and their interactions with potential drug candidates. In this chapter, we explore the principles, methodologies, applications, and advancements of MD simulations in the context of drug discovery. It highlights how MD simulations can provide detailed insights into biomolecular systems' structural dynamics, energetics, and kinetics, facilitating the rational design of novel therapeutics. By shedding light on the remarkable potential of MD simulations, we aim to underscore their significance in accelerating the drug discovery process and driving the development of targeted drugs.

Keywords: Biomolecular interactions, Boundary conditions, Computer-aided drug discovery, Force field, Molecular dynamics, Newton's equation, Simulation box.

INTRODUCTION

Drug discovery is a complex and resource-intensive process that involves identifying and optimizing compounds to modulate biological targets and treat diseases. Traditional experimental methods alone are often time-consuming and costly, motivating the integration of computational approaches to expedite the drug discovery pipeline. Computer-aided drug discovery (CADD) combines computational techniques with experimental methods to enhance drug discovery efforts' efficiency and success rate. Molecular dynamics (MD) simulations, a fundamental tool within CADD, provide a detailed understanding of biomolecular systems' dynamic behavior and interactions. This section provides an overview of the significance of drug discovery and the role of MD simulations in facilitating the rational design of novel therapeutics [1].

Manos C. Vlasios

All rights reserved-© 2024 Bentham Science Publishers

Principles of Molecular Dynamics Simulations

Newton's equations of motion

Newton's equations of motion, formulated by Sir Isaac Newton in the 17th century, are fundamental principles that describe the motion of objects under the influence of forces. These equations provide a mathematical foundation for classical mechanics and have been instrumental in our understanding of the physical world.

Newton's three equations of motion are commonly called the first, second, and third laws of motion. Together, they form the basis for analyzing the behavior of objects in motion and the forces acting upon them. Let us explore each of these equations in more detail:

Newton's First Law of Motion (Law of Inertia)

The first law states that an object at rest will remain at rest, and an object in motion will continue moving at a constant velocity unless acted upon by an external force. In simpler terms, an entity will resist any change in its state of motion. This property is known as inertia. Mathematically, the first law can be expressed as:

$$\Sigma F = 0 \text{ (Sum of forces acting on an object is zero)}$$

This equation implies that if the net force acting on an object is zero, the object will remain in its current state of motion (at rest or at a constant velocity).

Newton's Second Law of Motion

The second law relates the net force acting on an object to its mass and acceleration. It states that the acceleration of an object is directly proportional to the net force applied to it and inversely proportional to its mass. Mathematically, the second law is given by the equation:

$$\Sigma F = ma \text{ (Sum of forces = mass } \times \text{ acceleration)}$$

This equation highlights that when a force acts on an object, it causes the object to accelerate in the direction of the force. The greater the force applied, the greater the acceleration produced, while a larger mass resists acceleration.

Newton's Third Law of Motion

The third law states that for every action, there is an equal and opposite reaction. This law emphasizes that whenever one object exerts a force on the second object,

the second object exerts an equal and opposite force on the first object. Mathematically, the third law can be represented as:

$$F_{1,2} = -F_{2,1} \text{ (Force exerted by object 1 on object 2 = Force exerted by object 2 on object 1)}$$

This law highlights the symmetry of forces and is essential for understanding interactions between objects. Forces always occur in pairs, and each force in the pair acts on a different object.

By applying these three laws of motion, physicists and engineers can analyze and predict the motion of objects under various conditions. These laws have enabled the development of countless technologies, from designing bridges and airplanes to space exploration missions.

It is important to note that Newton's equations of motion are valid within the realm of classical mechanics and approximate reality. At extremely high speeds or in situations involving tiny particles, these equations may not accurately describe the observed behavior, requiring the application of more advanced theories such as Einstein's theory of relativity or quantum mechanics.

Nevertheless, Newton's equations of motion remain a cornerstone of physics education and serve as a practical and accessible framework for understanding and analyzing the motion of objects in our everyday lives.

Force Fields and Potential Energy Functions

Force fields are mathematical models that describe the interactions between atoms in a system. They comprise two main components: bonded terms (representing covalent bonds, angles, and torsions) and non-bonded terms (representing van der Waals interactions and electrostatic forces). This section delves into the different force fields used in MD simulations and the potential energy functions that govern the system's behavior.

Integration Algorithms

Integration algorithms are employed to numerically solve the equations of motion and simulate the system's dynamics. This section discusses various integration algorithms, including Verlet and Leapfrog integration, highlighting their numerical stability and accuracy.

Pharmacophore Modelling and Virtual Screening

Abstract: Pharmacophore modeling and virtual screening are indispensable tools in modern drug discovery. Pharmacophore models define the essential features and spatial arrangement required for a molecule to interact with a specific target. Virtual screening, powered by computational algorithms, efficiently sifts through vast chemical libraries to identify potential drug candidates. Recent advances in machine learning and molecular dynamics simulations have further enhanced the accuracy and applicability of these methods. Pharmacophore modeling and virtual screening continue to play crucial roles in expediting the drug discovery process, offering a strategic advantage to pharmaceutical research.

Keywords: Drug design, *In silico*, Lead optimization, Modelling, Pharmacophore, Virtual screening.

INTRODUCTION

In the realm of drug discovery and development, the identification and optimization of novel therapeutic compounds are crucial. One of the fundamental steps in this process is pharmacophore modeling. This technique allows researchers to unravel the essential structural and chemical features required for a molecule to interact with its target. This chapter explores the concept of pharmacophore modeling, its significance in drug design, its applications in the pharmaceutical industry, and recent advancements in the field [1].

Virtual screening is a critical component of computer-aided drug discovery (CADD) that is pivotal in accelerating the identification of potential drug candidates. In the quest for new therapeutics, virtual screening utilizes computational methods to efficiently screen large chemical libraries and predict the likelihood of a molecule binding to a specific drug target. By narrowing the search space and prioritizing compounds with higher binding affinities, virtual screening significantly reduces the time and cost involved in the early stages of drug discovery. Virtual screening has gained prominence recently due to the exponential growth in available chemical compounds and advances in computational power and algorithms. It offers a powerful tool to complement exp-

experimental approaches in the drug discovery pipeline. By leveraging computational models and algorithms, virtual screening enables researchers to explore vast chemical space, identify potential hits, and guide subsequent experimental validation and optimization. We are providing an extensive overview of virtual screening techniques, encompassing their underlying principles, approaches, applications, challenges, and future perspectives in the field of CADD [2].

In computer-aided drug discovery (CADD), Quantitative Structure-Activity Relationship (QSAR) methods have emerged as powerful tools for predicting and understanding the relationship between the chemical structure of a molecule and its biological activity. QSAR models enable the rational design and optimization of drug candidates, contributing to the acceleration and cost-effectiveness of the drug discovery process.

Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) analysis is a powerful computational approach that enables the exploration of the relationship between the three-dimensional structure of molecules and their biological activity. By integrating structural information with activity data, 3D QSAR provides valuable insights into the structural features critical for training and aids in designing and optimizing novel drug candidates. We will glimpse the significance of 3D QSAR, its underlying principles, and its applications in drug discovery [3].

Computer-aided drug discovery (CADD) has emerged as an indispensable tool in developing new therapeutics. Within the realm of CADD, force fields play a vital role in understanding and predicting the behavior of molecules at the atomic level [4].

Pharmacophore Modelling: Unveiling the Key to Drug Design

Understanding Pharmacophore Modelling

Pharmacophore modeling can be defined as a computational approach used to decipher a ligand molecule's essential features necessary for binding to its biological target. These features typically include hydrogen bond acceptors and donors, hydrophobic regions, aromatic rings, and other specific structural elements. By identifying these features, pharmacophore models aid in developing new drugs or optimizing existing ones.

Process and Techniques

The process of pharmacophore modeling involves several key steps. Initially, a training set of ligands that exhibit activity against the target is selected, and their

structures and biological activities are studied. These ligands can either be obtained from experimental data or generated computationally. Subsequently, these ligands are aligned based on their active sites or standard chemical features, providing insights into the common structural elements required for activity [5].

Once the alignment is complete, a pharmacophore hypothesis is generated. This hypothesis is a spatial arrangement of the essential features identified during the alignment process. It serves as a 3D template or a guide for the design of new compounds. Several computational techniques can be employed to create pharmacophore models, including molecular docking, molecular dynamics simulations, and machine learning algorithms [6].

Significance in Drug Design

Pharmacophore modeling plays a pivotal role in drug design for several reasons. Firstly, it helps researchers understand the structure-activity relationship (SAR) between ligands and their targets. By identifying the essential features necessary for binding, pharmacophore modeling assists in rational drug design by providing a blueprint for developing novel compounds or modifying existing ones.

Secondly, pharmacophore modeling allows for the virtual screening of large chemical libraries. Using the generated pharmacophore model as a filter makes the identification of potential lead compounds with similar essential features to the pharmacophore hypothesis possible. This approach significantly reduces the time and resources required for experimental testing and enhances the efficiency of the drug discovery process [7].

Applications in the Pharmaceutical Industry

The pharmaceutical industry widely employs pharmacophore modeling in various drug discovery and development stages. It aids in lead identification, optimization, and virtual screening of compound libraries. Pharmacophore models can also be used to predict the activity of new compounds, guide the synthesis of chemical analogs, and optimize drug pharmacokinetics.

Furthermore, pharmacophore modeling finds applications beyond traditional small-molecule drug design. It has been successfully applied to developing peptide and protein-based therapeutics and creating enzyme inhibitors and receptor ligands. The versatility of pharmacophore modeling allows its integration into multiple aspects of pharmaceutical research, enhancing the chances of identifying effective and safe drugs [8].

CHAPTER 4

Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics

Abstract: Computer-aided drug discovery (CADD) has revolutionized the field of pharmaceutical research by speeding up the identification of potential drug candidates. Molecular docking, a well-known technique within CADD, plays a crucial role in predicting and evaluating the binding affinity of small molecules to target proteins. This essay explores the principles, methodologies, applications, and advancements of molecular docking in the context of drug discovery. Additionally, it highlights the impact of molecular docking in accelerating the development of targeted therapeutics. By shedding light on the remarkable potential of molecular docking, this essay aims to underscore its significance in the ongoing pursuit of novel drugs and personalized medicine.

Keywords: Electrostatic interactions, Hydrogen bonding, *In silico* techniques, Molecular docking, Protein-ligand interactions, Scoring functions, Target identification.

INTRODUCTION

In recent decades, the rapid advancement of computational techniques has transformed the drug discovery landscape. Computer-aided drug discovery (CADD) approaches have become indispensable tools for rationalizing novel therapeutics. These techniques have the potential to accelerate the drug development process, minimize costs, and reduce reliance on time-consuming and expensive experimental procedures. The significance of drug discovery is finding effective drugs that are paramount in healthcare, offering potential treatments and cures for numerous diseases. However, the traditional drug discovery pipeline is a lengthy and arduous process involving high costs and attrition. Therefore, integrating computational methods, particularly molecular docking, has revolutionized the field by aiding in identification, optimization, and development of potential drug candidates. Molecular docking is a computational technique that predicts and evaluates the binding interactions between small molecules (ligands)

and target proteins. Researchers can estimate ligands' binding affinity and orientation within the protein's active site by simulating the docking process. This information is crucial for understanding the molecular basis of drug-target interactions and facilitating the design of potent and selective compounds [1, 2].

Principles of Molecular Docking

Protein-ligand Interaction

Protein-ligand interaction is crucial in many aspects of drug discovery and development. Molecular docking is a computational technique to predict the binding mode and affinity between a protein receptor and a small molecule ligand. It provides insights into the structural and energetic aspects of protein-ligand interactions, aiding in designing new drugs or optimizing existing ones.

A protein and a ligand interact primarily through noncovalent interactions, such as hydrogen bonds, hydrophobic interactions, electrostatic interactions, and van der Waals forces. These interactions are responsible for the formation and stabilization of the protein-ligand complex [3].

The protein and ligand are typically represented as rigid bodies during the molecular docking process, and their three-dimensional structures are used as input. The goal is to find the ligand's most favorable orientation and conformation within the protein's binding site, maximizing the complementarity between the two molecules [4].

Scoring functions evaluate and rank the binding poses generated during molecular docking. These scoring functions estimate the binding free energy or affinity between the protein and ligand, considering both the favorable and unfavorable interactions. They consider various factors, including shape complementarity, desolvation energy, electrostatic interactions, and van der Waals interactions.

Protein flexibility is an essential consideration in protein-ligand docking. Proteins can exhibit conformational changes upon ligand binding, known as induced fit or conformational selection. Accounting for protein flexibility can improve the accuracy of docking predictions by considering the adaptability of the protein's binding site [5].

Molecular docking techniques can be further enhanced by incorporating additional information, such as protein-ligand interaction fingerprints, covalent docking, or ensemble docking. These approaches aim to capture specific features of the protein-ligand interaction or explore multiple protein conformations, respectively, to obtain more reliable docking results [6].

Experimental validation, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, is necessary to confirm the accuracy of predicted protein-ligand interactions. These techniques provide high-resolution structural information about the protein-ligand complex, helping to validate the computational docking results and guide further optimization.

In summary, protein-ligand interaction in molecular docking involves predicting and analyzing the binding mode and affinity between a protein receptor and a small molecule ligand. Researchers can gain valuable insights into the complex interplay of noncovalent interactions that govern protein-ligand recognition by leveraging computational methods and scoring functions. This knowledge is instrumental in rational drug design and discovery processes [7].

Docking Algorithms

Rigid-body Docking

The algorithms assume that the protein receptor and ligand remain rigid during binding. These methods explore the translational and rotational space of the ligand within the protein's binding site to find the optimal pose. Examples of rigid-body docking algorithms include Fast Fourier Transform (FFT)-based methods like AutoDock, and geometric matching algorithms like DOCK [8].

Flexible Docking

Flexible docking algorithms account for the flexibility of the protein receptor, ligand, or both. Protein flexibility can be addressed by allowing limited conformational changes in the protein receptor during docking. Ligand flexibility can be considered by sampling different ligand conformations or employing molecular dynamics simulations. Flexible docking algorithms provide a more accurate representation of the protein-ligand interaction. Examples of flexible docking tools include AutoDock Vina, GOLD, and FlexX [9].

Ligand-Based Docking

Ligand-based docking methods focus on the properties and features of the ligand molecule to predict its binding affinity and orientation. These algorithms utilize databases of known ligand structures and employ similarity searching or pharmacophore-based approaches to identify potential binding modes and rank ligands according to their predicted binding affinities. Ligand-based docking is proper when the protein receptor structure is unknown or difficult to obtain. Examples of ligand-based docking algorithms include virtual screening techni-

CHAPTER 5

The Use of Density Functional Theory in Computer-Aided Drug Discovery

Abstract: Density Functional Theory (DFT) has become a cornerstone in Computer-Aided Drug Discovery (CADD), providing accurate insights into molecular interactions and properties. By predicting binding affinities, electronic structure, and molecular properties, DFT aids in rational drug design. DFT facilitates the exploration of crucial pharmacological factors, such as protein-ligand interactions and drug metabolism. Its computational efficiency enables high-throughput virtual screening, reducing time and costs in drug development. Continuous advancements in DFT methodologies and computational resources enhance its applicability in CADD. DFT in CADD is poised to accelerate the discovery of safer and more effective drugs, revolutionizing pharmaceutical research.

Keywords: Binding affinity, Computational techniques, Density functional theory, Drug discovery, Electron density, Electronic structure, Exchange-correlation, Quantum chemistry.

INTRODUCTION

Computer-aided drug discovery (CADD) has revolutionized the process of drug development, allowing scientists to accelerate the identification and optimization of potential therapeutic compounds. One powerful computational tool CADD uses is Density Functional Theory (DFT), which provides insights into molecules' electronic structure and properties [1]. Now we will explore DFT's principles, applications, advancements, challenges, and prospects in drug discovery.

Principles of Density Functional Theory

Density Functional Theory (DFT) is a widely used computational method in quantum mechanics and condensed matter physics. It provides a framework for studying the electronic structure and properties of atoms, molecules, and solids. Here are some fundamental principles of Density Functional Theory:

Manos C. Vlasios

All rights reserved-© 2024 Bentham Science Publishers

Electron Density

DFT is based on the concept of electron density rather than wave functions. The electron density, represented by the function $\rho(\mathbf{r})$, gives the probability of finding an electron at a particular point in space. In DFT, the total energy of a system is expressed as a function of the electron density [2, 3].

Hohenberg-Kohn Theorems

The Hohenberg-Kohn theorems form the foundation of DFT. They state that the electron density uniquely determines the external potential energy of a system and, thus, the total energy. This implies that the ground-state properties of a system can be selected from the electron density alone [4].

Kohn-Sham Equations

To practically implement DFT, the Kohn-Sham equations are employed. These equations introduce a set of fictitious non-interacting electrons that experience an effective potential, which is determined self-consistently from the electron density. Solving the Kohn-Sham equations yields the electron density and the electronic structure of the system [5].

Exchange-Correlation Functional

The exchange-correlation functional is a crucial component of DFT. It accounts for the effects of electron-electron interactions beyond the simple electron density. The exchange term describes the quantum mechanical exchange effect, while the correlation term incorporates the electron-electron interactions. Accurate approximations for the exchange-correlation functional are necessary for reliable DFT calculations [6].

Approximations

Due to the complexity of the exchange-correlation functional, practical calculations often rely on various approximations. The most common approximation is the local density approximation (LDA) or the generalized gradient approximation (GGA). More advanced approximations, such as hybrid functionals and meta-GGA functionals, aim to improve accuracy further.

Energy and Property Calculations

DFT provides a versatile tool for calculating various properties of systems, including total energies, molecular geometries, electronic band structures, and vi-

brational frequencies. These calculations enable the prediction and understanding of different materials and chemical processes [7].

Applications

Density Functional Theory has found extensive applications in studying atoms, molecules, surfaces, and solids. It has been employed in diverse fields such as catalysis, materials science, drug discovery, and nanotechnology. DFT calculations are used to investigate and design new materials, predict reaction mechanisms, and interpret experimental observations.

Density Functional Theory has revolutionized computational materials science and quantum chemistry, offering a powerful and efficient approach to investigating matter's electronic structure and properties. Its principles and applications continue to advance our understanding of fundamental phenomena and drive technological advancements [8].

Application of Density Functional Theory in Drug Discovery

Density Functional Theory (DFT) plays a significant role in drug discovery and development, offering valuable insights into drug molecules' molecular properties, reactivity, and interactions. Here are some critical applications of DFT in drug discovery:

Molecular Structure and Conformation

DFT calculations determine drug molecules' stable conformations and geometries. By predicting accurate molecular structures, DFT helps understand the three-dimensional arrangement of atoms and functional groups, which is crucial for studying their interactions with biological targets [9, 10].

Electronic Properties and Spectroscopy

DFT enables calculating electronic properties such as ionization potentials, electron affinities, and molecular orbitals. These properties provide insights into drug molecules' stability, reactivity, and electronic transitions. Additionally, DFT is used to simulate and interpret spectroscopic data, including UV-Vis, IR, and NMR spectra, which aid in characterizing drug compounds [11].

Reaction Energetics and Mechanisms

DFT calculations are instrumental in studying reaction energetics and elucidating reaction mechanisms. They provide valuable information about reaction barriers, reaction rates, and the thermodynamics of drug metabolism. By understanding the

CHAPTER 6**Software in Computer-Aided Drug Discovery:
Empowering Scientific Exploration and Innovation**

Abstract: Software has become an indispensable driving force in Computer-Aided Drug Discovery (CADD), facilitating target identification, molecular modeling, and virtual screening. Through bioinformatics and computational biology, software aids in the efficient identification of drug targets. Molecular modeling software empowers rational drug design by predicting molecular interactions and structures. Virtual screening software accelerates hit-to-lead optimization, efficiently sifting through chemical libraries. Machine learning algorithms and big data analytics enhance predictive modeling and biomarker discovery, enabling personalized medicine. Collaborative platforms and cloud-based solutions foster interdisciplinary collaboration, streamlining the drug discovery process. Software in CADD reduces costs, shortens development timelines, and fuels innovation, offering unprecedented possibilities for novel therapeutics and improved healthcare outcomes.

Keywords: Chemoinformatics, Computer-aided, Drug discovery, Molecular modeling, Software applications.

INTRODUCTION

Computer-aided drug discovery (CADD) has revolutionized the field of pharmaceutical research, accelerating the identification and optimization of novel therapeutics. A wide array of software tools and platforms are instrumental in facilitating various stages of the drug discovery process. This explores CADD's diverse software, functionalities, and impact on drug design and development. Computer-aided drug discovery (CADD) relies on robust hardware infrastructure to handle the complex computational demands of simulating molecular interactions, analyzing large datasets, and optimizing drug candidates [1, 2]. This chapter explores the role of hardware in CADD, including high-performance computing (HPC) systems, specialized hardware accelerators, and cloud computing platforms, and their impact on the efficiency and effectiveness of drug discovery and development.

Manos C. Vlasios

All rights reserved-© 2024 Bentham Science Publishers

Artificial Intelligence (AI) has emerged as a powerful tool in various scientific fields, and its application in computer-aided drug discovery (CADD) has revolutionized the process of therapeutic development [3, 4]. By leveraging AI algorithms and machine learning techniques, researchers have significantly enhanced their ability to analyze complex biological data, predict molecular properties, and expedite the identification of novel drug candidates. Herein, we are exploring the profound impact of AI in CADD, highlighting its role in accelerating drug discovery, optimizing lead identification, and enabling personalized medicine.

Molecular Modeling and Visualization Software

Molecular modeling software enables the visualization and manipulation of molecular structures, empowering researchers to analyze and understand the properties of compounds. These tools facilitate the construction, modification, and optimization of small molecules, proteins, nucleic acids, and other biomolecules. Widely used software includes:

Schrödinger Suite

An integrated suite of programs offering a range of molecular modeling and simulation tools for structure-based drug design, ligand docking, virtual screening, and molecular dynamics simulations [5].

PyMOL

A powerful molecular visualization tool to create high-quality 3D representations of molecules and analyze protein structures and ligand interactions [6].

Discovery Studio

A comprehensive software package providing a wide range of tools for protein and petite molecule modeling, virtual screening, and pharmacophore-based drug design.

Molecular Docking and Virtual Screening Software

Molecular docking and virtual screening software are crucial in predicting small molecules' binding affinity and orientation to target proteins. These tools aid in the identification of potential lead compounds for further optimization [7 - 9]. Notable software platforms include:

Autodock

A widely used molecular docking software that employs various algorithms to predict ligand binding modes and energies.

Gold (Genetic Optimization for Ligand Docking)

A docking software that utilizes genetic algorithms to explore ligand conformations and optimize ligand-protein interactions.

Dock

A program that combines shape complementarity and electrostatics to predict ligand binding poses and scores for virtual screening purposes.

Molecular Dynamics Simulation Software

Molecular dynamics (MD) simulation software allows researchers to study the dynamic behavior of molecules over time. These simulations provide insights into protein-ligand interactions, conformational changes, and the stability of drug-target complexes [10, 11]. Prominent MD simulation software includes:

Gromacs

A versatile molecular dynamics simulation package that supports various force fields, algorithms, and analysis tools.

Amber (Assisted Model Building with Energy Refinement)

A suite of programs for simulating biomolecular systems, including proteins, nucleic acids, and carbohydrates.

Namd

A scalable molecular dynamics software focusing on large biomolecular systems and parallel computing.

Cheminformatics and Drug Design Software

Cheminformatics and drug design software leverage computational techniques to analyze chemical data, design novel compounds, and predict their properties. These tools aid in lead optimization, scaffold hopping, and property prediction. Noteworthy software platforms include:

Success Stories in Computer-Aided Drug Discovery

Abstract: Computer-Aided Drug Discovery (CADD) has yielded remarkable successes, transforming the pharmaceutical landscape. Notable achievements include the development of kinase inhibitors for cancer treatment and repurposing of drugs for emerging health crises like COVID-19. CADD's role in personalized medicine is exemplified by tailored therapies for genetically defined patient groups in cancer treatment. Moreover, CADD has enhanced drug development efficiency, minimizing attrition rates and reducing costs for pharmaceutical companies. These successes illustrate the pivotal role of CADD in addressing complex diseases, streamlining drug development, and improving healthcare outcomes. Continuous advancements in computational techniques and interdisciplinary collaboration promise further breakthroughs in the field.

Keywords: Computer-aided, Drug discovery, Drug development, Pharmacophore analysis, Target identification, Virtual screening.

INTRODUCTION

Computer-aided drug discovery has revolutionized the process of developing novel therapeutics. One notable success story is the discovery of imatinib, a breakthrough drug that has transformed the treatment landscape for chronic myeloid leukemia (CML). This success story showcases the power of computational approaches in identifying and optimizing drug candidates with exceptional efficacy and safety profiles [1, 2]. Let us explore how computer-aided drug discovery played a pivotal role in the development of imatinib. Computer-aided drug discovery has played a pivotal role in developing innovative therapies, including immunotherapies for cancer treatment. One remarkable success story is the discovery of pembrolizumab, a breakthrough drug that has revolutionized the field of cancer immunotherapy [3, 4]. This story highlights the transformative impact of computational approaches in identifying novel drug targets and optimizing therapeutic candidates. How computer-aided drug discovery contributes to developing pembrolizumab? Computer-aided drug discovery has played a significant role in developing therapeutics for infectious diseases. One

notable success story is the discovery of sofosbuvir, marketed as Sovaldi, a breakthrough drug that has revolutionized the treatment of hepatitis C virus (HCV) infection. This demonstrates how computational approaches have contributed to identifying drug targets, designing highly potent antiviral agents, and optimizing treatment regimens [5, 6]. Computer-aided drug discovery has revolutionized the field of oncology by facilitating the development of targeted therapies. One remarkable success story is the discovery of osimertinib, a breakthrough drug that has transformed the treatment landscape for non-small cell lung cancer (NSCLC) patients with specific genetic mutations [7, 8]. This success story highlights the pivotal role of computational approaches in identifying novel drug targets, optimizing therapeutic candidates, and personalizing cancer treatment. Let us explore how computer-aided drug discovery contributed to the development of Osimertinib.

Development of Imatinib for Chronic Myeloid Leukemia

Target Identification

The first step in drug discovery is identifying a suitable target. In the case of CML, researchers aimed to target the aberrant fusion protein known as BCR-ABL, which drives the growth of leukemic cells. Computational methods, such as molecular modeling and bioinformatics, were employed to study the structure and function of BCR-ABL, providing crucial insights into its active site and interactions.

Virtual Screening

Virtual screening involves using computational tools to screen large databases of compounds and identify potential drug candidates that can interact with the target of interest. In case of imatinib, virtual screening techniques were employed to search chemical databases for molecules that could fit into the active site of BCR-ABL and inhibit its activity. Using various scoring functions and filters, virtual screening narrowed down the pool of potential compounds, including imatinib, as a promising candidate for further investigation.

Structure-Based Drug Design

Once imatinib was identified as a potential candidate, structure-based drug design techniques were utilized to optimize its chemical structure and improve its binding affinity and selectivity for BCR-ABL. Computational simulations, such as molecular docking and molecular dynamics, were performed to analyze the interactions between imatinib and the target protein. These simulations guided

medicinal chemists in modifying the chemical structure of imatinib to enhance its binding interactions and improve its pharmacokinetic properties.

Pharmacophore Analysis

Pharmacophore analysis involves identifying essential structural and chemical features required for a molecule to exhibit the desired biological activity. In case of imatinib, pharmacophore analysis played a crucial role in understanding the critical interactions between the drug and its target. By identifying the pharmacophoric features responsible for inhibiting BCR-ABL, researchers gained insights into the structural requirements for potent activity against the target.

Clinical Validation and Success

Imatinib, developed with computer-aided drug discovery, underwent rigorous preclinical and clinical testing. Clinical trials demonstrated its remarkable efficacy and safety in treating CML patients, leading to its approval by regulatory authorities. Imatinib was the first tyrosine kinase inhibitor (TKI) approved for CML, and its introduction revolutionized the treatment landscape. It achieved unprecedented response rates, improved patient outcomes, and transformed CML from a life-threatening disease to a manageable condition.

Development of Pembrolizumab for Cancer Immunotherapy

Target Identification

Pembrolizumab targets the programmed death-1 (PD-1) receptor pathway, critical in regulating immune responses. Computational techniques, such as protein structure prediction and molecular modeling, were employed to study the structure and function of PD-1 and its interactions with its ligands. These computational insights provided a foundation for understanding the potential of targeting PD-1 for cancer immunotherapy.

Virtual Screening and Ligand Design

Virtual screening methods were employed to identify small molecules or antibodies that could interact with PD-1 and modulate its activity. Large compound libraries or antibody databases were screened computationally to identify potential candidates with favorable binding profiles and therapeutic potential. In case of pembrolizumab, virtual screening techniques aided in identifying and designing antibodies that specifically targeted PD-1, blocking its interaction with its ligands and reinvigorating the immune response against cancer cells.

CHAPTER 8

The Future of Computer-Aided Drug Discovery Methods: Advancements and Opportunities

Abstract: The future of Computer-Aided Drug Discovery (CADD) methods is characterized by transformative innovations. Artificial intelligence and machine learning are enhancing accuracy in predicting drug-target interactions and pharmacokinetics, with deep learning models leading in performance. Quantum computing is poised to revolutionize molecular simulations. Big data and omics integration enable precision medicine, tailoring treatments to individual patient profiles. Cloud-based platforms democratize CADD tools and promote global collaboration. Ethical considerations, data privacy, and regulatory challenges are gaining prominence. With robust ethical guidelines and regulatory frameworks, the future of CADD promises safer and more efficient drug discovery, ensuring that novel therapies meet the diverse needs of patients worldwide.

Keywords: Applications, Artificial intelligence, Computer-aided, Drug discovery, Future, Quantum computing.

INTRODUCTION

Computer-aided drug discovery (CADD) has revolutionized the process of therapeutic development, leveraging computational techniques to expedite the identification of novel drug candidates. As technology advances, the future of CADD holds immense promise for further transforming the field [1, 2]. Here we will explore the potential advancements and opportunities, in integrating artificial intelligence, high-performance computing, multi-omics data, quantum computing, and emerging technologies such as blockchain and nanotechnology.

Integration of Artificial Intelligence (AI)

Artificial intelligence (AI) has already made significant contributions to CADD, and its integration is expected to play a central role in shaping the future of drug discovery. AI algorithms and machine learning techniques will continue to advance, allowing for more accurate prediction of molecular properties, improved virtual screening capabilities, and enhanced *de novo* drug design. As AI models learn from vast datasets and generate novel hypotheses, they will facilitate the ide-

ntification of drug candidates with high success rates, reducing the need for extensive experimental screening [3, 4].

Furthermore, AI will contribute to the development of personalized medicine by analyzing patient-specific data, such as genomics, proteomics, and clinical records. This customized approach will enable the design of targeted therapies tailored to individual patients, maximizing treatment efficacy while minimizing adverse effects. AI algorithms will leverage patient data to predict treatment responses, optimize dosages, and identify potential adverse events, leading to more precise and personalized drug therapies.

High-Performance Computing (HPC)

Advancements in **high-performance computing** (HPC) will significantly enhance the capabilities of CADD methods. The processing power provided by HPC systems will enable more extensive molecular dynamics simulations, allowing for longer and more accurate simulations of complex biological processes. This will provide deeper insights into protein-ligand interactions, protein dynamics, and the behavior of drug candidates within the human body.

Moreover, HPC will facilitate large-scale virtual screening campaigns by enabling the rapid evaluation of massive compound libraries against multiple drug targets. This scalability will accelerate lead identification and optimization, streamlining drug discovery. Additionally, HPC will support integrating multi-omics data and analyzing large datasets, enabling the extraction of meaningful patterns and correlations that can guide drug discovery efforts [5].

Integration of Multi-Omics Data

Integrating multi-omics data, including genomics, proteomics, metabolomics, and transcriptomics, holds tremendous potential for advancing CADD. By combining diverse biological data, researchers can comprehensively understand disease mechanisms, identify novel drug targets, and predict patient response to specific treatments. Integrating multi-omics data with AI algorithms will enable the development of predictive models that can guide the selection of drug candidates with higher precision and efficacy.

For example, by analyzing genomic data, researchers can identify genetic variations associated with drug response, enabling the development of personalized treatment regimens. Integrating proteomic and metabolomic data can provide insights into the dynamic changes occurring in disease states and the ans-

wer to drug interventions. Researchers can extract meaningful information from multi-omics data and uncover new therapeutic opportunities by leveraging AI techniques like data mining, pattern recognition, and network analysis [6].

Repurposing and Drug Combination Strategies

The future of CADD will see an increased emphasis on drug repurposing and drug combination strategies. With extensive databases and AI-driven algorithms, researchers can identify new therapeutic uses for existing drugs, expediting the development of treatments for various diseases.

Additionally, the exploration of synergistic drug combinations will continue to gain prominence. AI algorithms will assist in predicting effective drug combinations and optimizing dosages, leading to enhanced treatment outcomes and improved patient care. Integrating multi-omics data with AI-driven approaches will provide a deeper understanding of the interactions between drugs, targets, and disease pathways, enabling the identification of synergistic drug combinations with improved efficacy and reduced side effects.

Quantum Computing

Quantum computing holds enormous potential for CADD, offering the capability to solve complex problems at an unprecedented speed. Quantum algorithms can potentially revolutionize drug discovery by efficiently simulating chemical reactions, predicting protein-ligand interactions with high accuracy, and enabling more precise optimization of drug candidates.

While quantum computing is still in its early stages, advancements in this field could revolutionize the efficiency and scope of CADD methods, unlocking new avenues for drug discovery. Quantum computers have the potential to rapidly search vast chemical space, providing valuable insights into the design of novel molecules and the exploration of alternative drug scaffolds.

Integration of Blockchain Technology

Integrating blockchain technology in CADD promises to improve data security, integrity, and transparency. Blockchain can provide a decentralized and immutable ledger for storing and sharing sensitive data, such as clinical trial results and patient information. Blockchain technology can enhance collaboration between researchers, pharmaceutical companies, and regulatory authorities by ensuring data integrity and facilitating secure data exchange. This can accelerate drug discovery, promote trust and transparency, and enable more efficient drug development and regulatory approval.

SUBJECT INDEX

A

Absorption 2, 9, 11, 13, 55, 79, 116, 117, 118
distribution, metabolism, excretion (ADME)
2, 9, 11, 55, 79, 116, 117, 118
influencing drug 13
Acids, nucleic 36, 104, 105
ADME processes 13
Algorithms 48, 49, 51, 65, 85, 86, 104, 105,
107, 109, 110, 111, 126, 127, 128
geometric matching 65
Allosteric 26, 31
communication pathways 26
modulation 31
Analyzing 18, 19, 26, 28, 29, 30, 32, 65, 117,
127
cancer genomics data 117
genomic data 127
Antibodies, designing therapeutic 120
Antiviral agents 113
Applications 53, 103
of virtual screening in drug discovery 53
software 103
Artificial intelligence 4, 6, 51, 53, 54, 55, 87,
104, 109, 110, 111, 122, 126, 129
integration of 110, 126
and machine learning 122, 126
techniques 51, 53, 87

C

Cancer(s) 112, 114, 115
immunotherapy 112, 114, 115
bladder 115
Cheminformatics 105, 106, 110
and drug design software 105
Chemistry, combinatorial 70
ChemMine tools 106
Chronic myeloid leukemia (CML) 112, 113,
114
Circular dichroism (CD) 35
Cloud 103, 108, 110

-based solutions 103
computing platforms 103, 108, 110
Coarse-graining techniques 43
Combination therapies 110, 116
Communication networks 29
Comparing simulated NMR observables 36
Computational 2, 3, 5, 6, 10, 29, 31, 33, 34,
43, 48, 50, 52, 55, 59, 60, 63, 64, 77, 79,
80, 83, 86, 88, 91, 100, 106, 107, 112,
113, 114, 115, 116, 117, 118, 120, 122,
123
algorithms 48
algorithms and scoring functions 116
analyses and scoring functions 118
analysis process 79
framework, robust 60
methods 5, 6, 29, 31, 33, 77, 80, 83, 113,
115, 116, 117, 120
modeling techniques 115, 117
power 43, 48, 59, 86, 106
tasks 107
techniques 2, 3, 50, 52, 55, 63, 64, 88, 91,
112, 114, 117, 118, 122, 123
tools 10, 113
Computer-aided drug 116, 117, 119, 123
design techniques 116, 117
discovery techniques 119, 123
Computer hardware and software
advancements 51
Computing 43, 54, 87
cloud 54, 87
resource, single 43
techniques 43
Conditions, thermodynamic 20
Conformational changes 26, 27, 28, 31, 33,
34, 36, 38, 41, 51, 53, 59, 60
Conformations, molecular 24
Covalent bond behavior 58
COVID-19 110, 112, 119, 120, 121, 122, 123
pandemic 119, 123
symptoms 120
therapy 119

- treatment 120
 - Cryo-electron microscopy 53, 70
 - Crystallographic data 38
- D**
- Data 76, 99, 108, 128
 - availability and integration 99
 - mining techniques 76
 - security 128
 - storage 108
 - Data analysis 1, 4, 106, 110, 111, 117
 - and machine learning software 106
 - genomic 117
 - Databases 11, 65, 72, 73, 74, 76, 81, 114, 128
 - antibody 114
 - gene expression 76
 - protein-protein interaction 76
 - Density functional theory 91, 93, 95, 96, 98, 100
 - Development 113, 114, 115, 117
 - of imatinib for chronic myeloid leukemia 113
 - of osimertinib for non-small cell lung cancer 117
 - of pembrolizumab for cancer immunotherapy 114
 - of sovaldi for hepatitis 115
 - Dielectric constant 97, 98
 - Discovery processes 65
 - Disease(s) 1, 2, 4, 5, 6, 63, 70, 73, 75, 76, 77, 110, 111, 112, 114, 128
 - addressing complex 112
 - associated proteins 5
 - infectious 112
 - life-threatening 114
 - pathways 2, 70, 128
 - phenotypes 4
 - progression 77
 - relevant phenotypes 5
 - relevant processes 76
 - Docking 34, 51, 65, 66, 69, 70, 71, 73, 74, 75, 76, 83, 84
 - fragment-based 83, 84
 - algorithm selection 74
 - algorithms 65, 70, 71, 73, 74
 - Docking simulations 80, 81, 82, 84, 85, 86, 87, 115, 118
 - molecular 81, 82, 85, 86, 87, 115, 118
 - Docking software 105
 - molecular 105
 - Docking techniques 34, 51, 64, 83, 86, 120
 - molecular 51, 64, 83, 86, 120
 - Drug 9, 10, 12, 13, 14, 15, 30, 34, 91, 93, 105, 110, 116, 121, 122
 - binding 30, 34, 121
 - Design Software 105
 - design software leverage computational techniques 105
 - drug interactions 9, 10, 13, 14, 15
 - lipophilicity 13
 - metabolism 10, 12, 13, 91, 93, 116
 - protein interactions 30
 - repurposing efforts 110, 122
 - Drug design 2, 9, 14, 48, 49, 50, 51, 56, 70, 72, 94, 98, 103, 104, 110
 - computer-aided 70
 - ligand-based 56, 72
 - pharmacophore-based 104
 - Drug development 2, 3, 6, 10, 13, 14, 15, 63, 75, 91, 110, 112, 121
 - efforts 75
 - process 3, 15, 63, 91
 - streamlining 112
 - Drug discovery 1, 9, 17, 33, 48, 49, 50, 54, 60, 84, 88, 103, 111, 121, 122, 127
 - efforts 17, 33, 121
 - methods 1
 - process 9, 17, 48, 49, 50, 54, 60, 84, 88, 103, 111
 - revolutionized computer-aided 60, 111
 - streamlining 127
 - workflows 122
 - Drug resistance 33, 34
 - mechanisms 33
 - mutants 34
 - Drug solubility 1, 2, 6, 7, 8, 14
 - enhancing 8
 - factors influence 7
 - Dynamics 21, 25, 26, 27, 28, 29, 34, 36, 37, 38, 41, 86, 87, 121
 - conformational 37, 38, 121
 - protein's 28
- E**
- Effective therapeutics 6, 33, 110
 - Effects 26, 40, 44, 76, 96
 - allosteric 26
 - electronic 40

mechanical 44, 96
phenotypic 76
Electron-electron interactions 92
Energies 24, 35, 43, 58, 59, 64, 67, 68, 74, 81,
95, 96, 105
activation 35
desolvation 64, 67, 74, 81
fitting force field 96
Environments 7, 21, 24, 26, 44, 59, 94
chemical 59
lipid-based 7
realistic 26
Enzymatic 13, 25, 40, 100
processes 13
reactions 25, 40, 100
Enzyme inhibitors 50
Epidermal growth factor receptor (EGFR) 117

F

Factors 2, 13, 14, 22, 30, 33, 64, 66, 67, 68,
69, 74, 82
critical 22
enrichment 69
Fast fourier transform (FFT) 39, 65
Field-programmable gate arrays (FPGAs) 107,
110
Flexibility in target proteins 34
Flexible docking algorithms 65
Fluorescence resonance energy transfer
(FRET) 35
Force field(s) 19, 20, 23, 24, 25, 26, 27, 33,
43, 44, 45, 58, 59, 60, 95, 96
accuracy 33, 45
and potential energy functions 19
combining 45
components 58
development 60
fitting 95
in computer-aided drug discovery 58
in molecular dynamics 95
methods 96
predictions of thermodynamic properties 24
Forces 18, 19, 30, 41, 58, 59, 81, 95, 96, 103
calculating atomic 59
electrostatic 19, 58, 95
Formation, metabolite 14
Fragment 70, 79, 83
-based design 70
-based methods 79

Library generation 83
Fragment merging 79
Free energy 32, 33, 82, 87
calculation methods 32, 87
perturbation (FEP) 32, 33, 82
Fuels innovation 103
Function 13, 20, 27, 28, 29, 35, 38, 39, 66, 67,
92, 97, 113, 114
hepatic 13
mathematical 20
Functional density theory 95

G

Gastrointestinal tract 12
Generalized gradient approximation (GGA)
92, 98
Genes 4, 117
disease-related 4
Genetic techniques 76
Genomics and proteomics technologies 75
Growth, exponential 48

H

Hardware in computer-aided drug discovery
106
HCV infection 116, 122
chronic 116
HCV treatment 116
Hepatitis 113, 115
C virus (HCV) 113, 115
High 3, 5, 43, 51, 53, 76, 87, 88, 100, 103,
106, 109, 110, 126, 127, 129
-performance computing (HPC) 43, 51, 87,
103, 106, 110, 126, 127, 129
-throughput screening (HTS) 3, 5, 53, 76,
88, 100, 109
Hybrid docking algorithms 66

I

Immune 115, 120
checkpoint inhibitors 115
response modulation 120
Inflammatory response 118
Influence drug binding 30
Integration 19, 32, 33, 39, 126, 127, 128
algorithms 19, 39
of blockchain technology 128

of multi-omics data 127
omics 126
thermodynamic 32, 33
Isothermal titration calorimetry (ITC) 76

K

Kohn-Sham equations 92

L

Law of Inertia 18
LBVS techniques 52
Ligand 51, 52, 60, 69, 85, 86, 104, 105
 docking 69, 104, 105
 properties 86
 -protein 85
 -target interactions 51, 52, 60
Ligand-based 51, 52, 56, 65, 72, 73
 docking algorithms 65
 drug design (LBDD) 56, 72, 73
 methods 52
 virtual screening (LBVS) 51, 52
Lipid 7, 8, 28
 -based formulations 7, 8
 -protein interactions 28
Local density approximation (LDA) 92, 98

M

Machine learning 1, 6, 10, 33, 45, 48, 50, 51, 53, 54, 55, 82, 87, 88, 100, 103, 104, 106, 107, 109, 122, 126
 algorithms 10, 50, 51, 53, 54, 55, 82, 103, 109
 applications 107
 methods 33, 87
 software 106
 techniques 33, 45, 88, 104, 126
Mass spectrometry 5
Membrane 27, 28, 29, 30, 88
 proteins 27, 28, 29, 30, 88
 transporters 30
Molecular 8, 11, 58, 59, 60, 72, 87, 91, 93, 104, 106, 110, 115, 118, 126
 fingerprinting 106
 fingerprints 72
 interactions 8, 58, 59, 60, 87, 91, 110, 115, 118
 modeling tools 106

 properties 11, 91, 93, 104, 126
Molecular docking 51, 74, 87, 104, 118
 algorithms 51, 74
 and binding analysis 118
 and virtual screening software 104
 predictions 87
 workflows 87
Molecular mechanics 32, 67, 100
 generalized born surface area (MMGBSA) 32
Molecular modeling 103, 104
 and visualization software 104
 software 103, 104
Multiple linear regression (MLR) 54
Mutant proteins 121
Mutations, genetic 113

N

Nanomedicines 129
Natural 6, 33, 53, 82
 product screening 6
 networks 33, 53, 82
Newton's 17, 18, 19, 26
 equations 17, 18, 19, 26
 first law 18
 second law 18
 third law 18
Next-generation sequencing 4
NMR 35, 36, 37, 70, 116
 spectroscopy 35, 36, 37, 70, 116
 techniques 36
Non-small cell lung cancer (NSCLC) 113, 117, 118
NS5B 116
Nuclear magnetic resonance (NMR) 35, 65, 68

O

Oncology 113, 123

P

Pathways 1, 4, 5, 11, 29, 75, 76, 117
 allosteric 29
 cancer cell signaling 117
 disease-related 76
 metabolic 11
Pembrolizumab targets 114

Popular docking algorithms 74
Principle(s) 17, 18, 45, 49, 51, 52, 54, 56, 57,
63, 64, 67, 88, 91, 93
 component analysis (PCA) 57
 computational modeling 51
 of density functional theory 91
 of molecular docking 64
 of molecular dynamics simulations 18
 of QSAR 54
Properties 2, 3, 9, 10, 14, 15, 24, 25, 26, 52,
54, 57, 58, 67, 72, 79, 91, 93, 96, 100,
116, 117
 dielectric 67
 drug-likeness 116
 electronic 52, 54, 93
 energetic 26, 58, 96
 pharmacodynamic 117
Protease 120, 121
Protein 5, 28, 41, 81
 activities 5
 conformational changes 81
 -ligand binding 41
 -lipid interactions 28
Protein-ligand 25, 37, 40, 59, 63, 64, 65, 67,
68, 81, 82, 84, 86, 87, 91, 94, 120, 121
 binding affinity 59
 complexes 25, 59, 68, 82, 120, 121
 docking 64
 interactions 37, 40, 63, 64, 65, 67, 68, 81,
84, 86, 87, 91, 94
 recognition 65
Protein-protein 25, 26, 27, 28, 36, 38, 41, 88
 binding 26
 interactions 25, 26, 27, 28, 36, 38, 41, 88
 -protein recognition 38
Proteomics technologies 75

Q

QSAR 56
 analysis aids 56
 methods 3, 54, 54, 55, 60
 in computer-aided drug discovery 54
 modeling 54, 60
 techniques 60
Quantitative structure-activity relationship
 (QSAR) 10, 49, 52, 54, 55, 56, 57, 60,
72, 115
Quantum mechanics 19, 59, 91

R

Receiver operating characteristic (ROC) 69
Replica exchange molecular dynamics
 (REMD) 31
Repurposable drugs 122
Resource(s) 15, 17, 42, 43, 50, 66, 108
 cloud computing 43
 hardware 43
 -intensive process 17
Revolutionizing therapeutic development 109
Rigid-body docking algorithms 65
RNA 76, 120,
 -dependent RNA polymerase 120
 interference (RNAi) 76
Root-mean-square 34, 38, 69
 deviation (RMSD) 34, 69
 error (RMSE) 69
 fluctuations (RMSF) 38

S

SARS-CoV-2 proteins 120
Scoring functions, learning-based 68
Signal transduction 25, 27
Silico techniques 63
Simulating membrane proteins 27
Simulation 26, 31, 104, 105
 software 105
 techniques 26
 tools 104
 trajectories 31
Software 51, 105
 advancements 51
 scalable molecular dynamics 105
Solvent 30, 38, 97
 -accessible surface areas (SASA) 38, 97
 -drug interactions 30
Spectroscopic data 93, 100
Spectroscopy 35, 65, 68, 93
Structure 3, 5, 50, 51, 52, 60, 70, 71, 78, 84,
104, 106, 113, 116, 117, 120, 122, 123
 -activity relationship (SAR) 3, 50, 60, 78,
84, 106, 116, 117
 -based drug design (SBDD) 70, 71, 104,
113, 116, 117, 120, 122, 123
 -based drug design techniques 113, 120
 -based virtual screening (SBVS) 5, 51, 52
Support vector machines (SVM) 33, 54
Surface plasmon resonance (SPR) 76

Systems, protein-ligand 66
System's thermodynamic behavior 24

T

Target 10, 32, 33, 34, 51, 63, 70, 73, 75, 76,
77, 78, 79, 80, 83, 117, 120
-based drug design 10
EGFR mutations 117
gene 76
protein 32, 33, 34, 51, 63, 70, 73, 75, 76,
77, 78, 79, 80, 83, 120
Three-dimensional quantitative structure-
activity relationship analysis 55
Traditional experimental methods 17
Transition state theory 99
Transporter inhibition 9
Tyrosine kinase inhibitor (TKI) 114

V

Viral proteins 119, 120, 121, 122
targeting 120
Viral replication 119, 120
Virtual screening 34, 49, 51, 65, 76, 103, 104,
107, 113, 114, 118
and ligand design 114, 118
calculations 107
process 34
software 103, 104
techniques 49, 51, 65, 113, 114, 118
tool 76

W

Waals forces 20, 24, 64
Water-mediated interactions 26, 82, 85, 86

X

X-ray crystallography 34, 37, 38, 53, 65, 68,
70, 116, 117

